
NYSEHealthcareMedical - Care Facilities
أحدث البيانات المتاحة
22.17 US$
+0.04 US$ · +0.18%
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
الإغلاق السابق
22.17 US$
+0.04 US$ · +0.18%
بعد ساعات التداول
22.29 US$
+0.12 US$ · +0.54%
16 أكتوبر، 7:53 م ET
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
نطاق اليوم
السعر الحالي 22.17 US$
نطاق 52 أسبوعًا
السعر الحالي 22.17 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
شراء
تقييم
89
قيمة جذابة جدًا
المشاعر
48
مختلط
المخاطر
29
مخاطر متوسطة
الزخم
43
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
نطاق اليوم
السعر الحالي 22.17 US$
نطاق 52 أسبوعًا
السعر الحالي 22.17 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (EUR) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 19.63 مليار EUR | 19.34 مليار EUR | 19.45 مليار EUR | 19.4 مليار EUR | 17.62 مليار EUR |
| تكلفة البضاعة المباعة | 14.6 مليار EUR | 14.58 مليار EUR | 14.53 مليار EUR | 14.5 مليار EUR | 12.85 مليار EUR |
| الربح الإجمالي | 5.03 مليار EUR | 4.76 مليار EUR | 4.93 مليار EUR | 4.89 مليار EUR | 4.77 مليار EUR |
| البحث والتطوير | 157.98 مليون EUR | 183.49 مليون EUR | 231.97 مليون EUR | 228.62 مليون EUR | 220.78 مليون EUR |
| مصاريف البيع والمصاريف العمومية والإدارية | 3.03 مليار EUR | 3.14 مليار EUR | 3.2 مليار EUR | 3.17 مليار EUR | 2.77 مليار EUR |
| نفقات التشغيل | 3.2 مليار EUR | 3.29 مليار EUR | 3.56 مليار EUR | 3.38 مليار EUR | 2.92 مليار EUR |
| دخل الفوائد | 69.61 مليون EUR | 71.58 مليون EUR | 88.22 مليون EUR | 67.66 مليون EUR | 73.17 مليون EUR |
| مصاريف الفوائد | 384.41 مليون EUR | 407.04 مليون EUR | 424.64 مليون EUR | 360.14 مليون EUR | 353.6 مليون EUR |
| الاستهلاك والإطفاء | 1.5 مليار EUR | 1.74 مليار EUR | 1.75 مليار EUR | 1.84 مليار EUR | 1.62 مليار EUR |
| الدخل التشغيلي | 1.83 مليار EUR | 1.47 مليار EUR | 1.37 مليار EUR | 1.51 مليار EUR | 1.85 مليار EUR |
| صافي الدخل | 978.37 مليون EUR | 537.91 مليون EUR | 499 مليون EUR | 673.41 مليون EUR | 969.31 مليون EUR |
تم تحديث حقائق الشركة 17 أكتوبر 2026.
النتائج المعلنة مع توقعات الإجماع المتاحة.
النتائج المعلنة مع توقعات الإجماع المتاحة.
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Pzena U.S. Large Cap Value ETFPZLV2.37 مليون3.30%72.2 مليون USD0.60%31.21 US$-0.14%
Avantis International Equity ETFAVDE1.34 مليون0.01%19.4 مليار USD0.23%90.07 US$+0.20%
iShares Flexible Equity Active ETFBFLX1.15 مليون0.05%2.18 مليار USD0.40%25.7165 US$-0.90%
ActivePassive International Equity ETFAPIE690.97 ألف0.06%1.14 مليار USD0.45%38.27 US$-0.55%
ETF Series Solutions - AAM Todd International Intrinsic Value ETFTIIV380.11 ألف1.18%32.03 مليون USD0.54%29.843 US$0.00%
ETF Opportunities Trust - Cultivar ETFCVAR296.74 ألف0.64%46.32 مليون USD0.87%31.377 US$-0.03%
Dimensional - International Core Equity Market ETFDFAI77.81 ألف0.00%18.17 مليار USD0.18%41.57 US$+0.14%
Dimensional - International Value ETFDFIV32.8 ألف0.00%22.11 مليار USD0.27%56.48 US$+0.59%
Pzena U.S. Large Cap Value ETFPZLV
Avantis International Equity ETFAVDE
iShares Flexible Equity Active ETFBFLX
ActivePassive International Equity ETFAPIE
ETF Series Solutions - AAM Todd International Intrinsic Value ETFTIIV
ETF Opportunities Trust - Cultivar ETFCVAR
Dimensional - International Core Equity Market ETFDFAI
Dimensional - International Value ETFDFIVالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.